{
  "docId": "019de075-3cec-7700-94db-076a5ce30d84",
  "docSlug": "8c2d629a90974743be7d15f16a23e50f",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 56,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide uses two charts: a dose-response curve (left) and a scatter plot (right) to demonstrate competitive advantage.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-3cec-7700-94db-076a5ce30d84/35",
  "deckHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84",
  "deckJsonHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84.json",
  "deckAnchorHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.02,
        "y": 0.37
      },
      "kind": "chart",
      "text": "Dose-response curve showing % Inhibition of TF-1 Apoptosis vs Antibody Concentration",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffd64bb7-8bbd-43f8-a4a3-d2b750d2ca49",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.35,
        "y": 0.37
      },
      "kind": "chart",
      "text": "Scatter plot of Relative DcR3/DR3 Blocking vs TF-1 Apoptosis Inhibition IC50",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27223b4f-e86e-4d12-abbe-ce8f71483307",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.7,
        "y": 0.2
      },
      "kind": "list",
      "text": "Spyre has multiple lead clones that have demonstrated superior potency as compared to PRA023. Diverse clones identified matching specificity profile with competitive antibodies. Development candidate to optimize against trimer and monomers, selectivity against decoy receptor.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76e40aef-e954-4fbb-8ca1-de4014403822",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "Specialized reagents required to generate monomeric/trimeric TL1A mAbs, likely limiting fast-follower competition",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d40e8abb-5bc6-4142-9594-8be44581349f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "De novo TL1A lead clones are highly potent and characteristically diverse",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "932297fb-fcc7-4ea4-b36b-cbf338ee9671",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 44,
      "from": 31,
      "beatId": "5c590fe3-bdd5-4bd1-85d4-420b5f2a4608",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence",
      "beatSlug": "evidence",
      "evidence": "The document provides evidence to support the company's solution",
      "position": 4,
      "confidence": 0.9,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}